SepsisORPICUNCT02114853
Oxidative Monitoring in ICU Patients.
An observational study of Sepsis, run by University of Thessaly at 1 site in Greece.
Trial summary
Sepsis is common in the ICU and is associated with high mortality that reaches up to 60%, increased duration of hospitalization and additional costs [1,2].Early diagnosis and stratification of severity are of great importance in order to timely apply proper and adequate treatment [3]. Read more about this study
- Who is it for?
- Ages 18 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Sepsis
- How many people
- 150 participants
- Where
- 1 siteGreece
- Study dates
- Apr 2014to Apr 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All subjects who enter to the intensive care unit are candidates for this protocol
Who may be able to join
- All subjects entering to the ICU and are expected to stay for more than 72 hours are eligible to participate.
- Sepsis is recognized, defined and categorized according to the Surviving Sepsis Campaign criteria [10].
Who cannot join
- patients who receive chronic renal replacement therapy, iii) age under 18, iv) patients with body mass index<18, v) antioxidant supplementation two weeks prior to ICU admission
Trial locations and contacts
1 site in 1 country.
Greece1 site, 1 recruiting
- Recruiting
ICU, University Hospital of Larissa
Larissa, Thessaly, 41110
Maria Karapetsa, MD, +302413501280, mkarapetsa@gmail.com
Epaminondas Zakynthinos, Professor of Intensive Care, +302413501566, ezakynth@med.uth.gr
About this study
Sepsis is common in the ICU and is associated with high mortality that reaches up to 60%, increased duration of hospitalization and additional costs [1,2].Early diagnosis and stratification of severity are of great importance in order to timely apply proper and adequate treatment [3].
Oxidative stress is implicated in inflammation and sepsis and sepsis severity seems to correlate with increased oxidative stress [7,8]. Monitoring of oxidative stress has been done so far with various markers which reflect the different pathways of oxidative stress as is oxidosis of lipids, proteins, nucleic acids; yet the antioxidant capacity of various enzymes and vitamins has been studied [9]. However these methods do not reflect oxidative stress as a whole, are time consuming, need special laboratory procedures and are costly.
Read more
Oxidation-reduction potential is a new technique that enables bedside assessment of the oxidative status. It is based on measuring the balance of oxidants and reductants in human blood with a simple plasma test that reports results immediately.
Hypothesis
Oxidation-reduction potential, used for oxidative monitoring in ICU patients, might correlate with sepsis severity and may be used in addition to other clinical and/or inflammatory markers to assess severity and possibly prognosis.
Read the detailed description
- Procedures/evaluation of the trial 4.1 Evaluation at entry
The selected oxidative parameters that will be assessed in this study will be:
oxidation-reduction potential (ORP) in plasma thiobarbituric acid-reactive substances (TBARS) in plasma protein carbonyls (CO) in plasma total antioxidant capacity in plasma (TAC)
The inflammatory parameters that will be measured are:
C-Reactive protein in plasma Brain Natriuretic Peptide (BNP) in whole blood Troponin-I in whole blood Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood
.2. Time of assessment Measurements will be performed within the first 24hours upon entry and daily regarding the ORP detection and oxidative markers for a period of 10 days, if sepsis is not present.
In the presence of sepsis diagnosis, measurements will be performed daily until the 7th day of the septic episode plus at the time of sepsis resolution or at the point of death and at the end of the follow-up period, on the 28th day.
For the inflammatory markers measurements will be performed as followed:
C-Reactive protein in plasma daily Brain Natriuretic Peptide (BNP) in whole blood at admission and/or sepsis diagnosis and every 72h until resolution/death and on the 28th day.
Troponin-I in whole blood at admission and/or sepsis diagnosis and during sepsis according to heart ultrasound findings and on the 28th day.
Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood
4.3. Blood collection and store Arterial blood from an indwelling arterial catheter will be drawn from each patient.
The blood will be kept in a tube with sodium heparin, immediately centrifuged at 1,370g and a small portion will be used for the detection of ORP while the remaining fraction will be collected and stored at -80o C until further analysis.
4.4. Assessment of the oxidative markers ORP will be immediately assessed using the device RedoxSYS of Luoxis (Ampio Pharmaceuticals Inc, CO, USA) The device reports two measurements static ORP, and capacity for every plasma sample [11 ].
For TBARS, a slightly modified assay of Keles et al. [12 ] will be used, while plasma protein carbonyls will be determined based on the method of Patsoukis et al. [13 ]. TAC determination will be based on a previously described method [14].
- Data collection
Data to be recorded for each subject are:
Past medical history Patients wil be divided in medical, surgical and trauma groups. (comprising patients with renal disease, diabetes, Chronic obstructive pulmonary disease, coronary artery disease, immunocompromized states, cerebrovascular disease).
Data to be recorded during ICU stay for each subject, are:
APACHE II score at entry SOFA score at enry and upon all other timepoints. Sepsis severity (sepsis, severe sepsis, septic shock), upon diagnosis and for the rest timepoints.
In all timepoints:
Oxygen concentration (FiO2), partial oxygen pressure , mode of mechanical ventilation, static compliance, tidal volume.
Blood pH Blood lactate Levels of vasopressors and inotropes (noradrenaline, adrenaline, dopamine, dobutamine, vasopressin. The peak dose will be recorded within the last 24h).
Temperature (peak value in the last 24h)
Every day a full blood count and biochemical examinations will take place. Data to be recorded in all timepoints are:
Blood leukocyte count Platelets Fibrinogen Prothrombin time/Partial thromboplastin time Urea/Creatinine Transaminases Bilirubin (total, conjugated) Uric acid Blood albumin (every 3 days).
In addition :
Surveillance cultures upon entry. Blood, bronchial secretions, urine cultures at sepsis diagnosis and of any other fluid or tissue connected with the sepsis cause according to the attending physician. Specimens of all cultures will be repeated during the septic episode according to the attending physician's opinion and will also be recorded.
- Conditions
- Sepsis
- Medical subject headings
- Sepsis
What is being measured
The primary outcome is the main question the study is designed to answer.
Sepsis severity
Measured: Time of sepsis diagnosis
Secondary outcomes (2)
mortality
Measured: 28th day
ICU outcome
Measured: within 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2014 (estimated)
- Study startApr 2014
- Primary completionJan 2015 (estimated)
- Study completionApr 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SepsisStudies of the same condition, open and under way.
- More trials run by University of ThessalyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Thessaly
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maria Karapetsa, University of Thessaly
- Investigators
- Epaminondas Zakynthinos, Prof., Principal investigator, University of ThessalyMaria Karapetsa, MD, Principal investigator, University of Thessaly-University Hospital of Larissa,ICU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02114853
- Sponsor's protocol ID
- 4784.02
- Acronym
- ORPICU
- Status last verified
- Apr 2014
- First submitted
- 12 Apr 2014
- Last updated
- 15 Apr 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oxidative Monitoring in ICU Patients.
- ClinicalTrials.gov ID
- NCT02114853
- Acronym / sponsor ID
- ORPICU / 4784.02
- Conditions
- Sepsis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University of ThessalyUniversity, hospital or other
- Study start
- Apr 2014
- Primary completion
- Jan 2015 (estimated)
- Study completion
- Apr 2016 (estimated)
- First posted
- 15 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sepsis is common in the ICU and is associated with high mortality that reaches up to 60%, increased duration of hospitalization and additional costs [1,2].Early diagnosis and stratification of severity are of great importance in order to timely apply proper and adequate treatment [3].
Oxidative stress is implicated in inflammation and sepsis and sepsis severity seems to correlate with increased oxidative stress [7,8]. Monitoring of oxidative stress has been done so far with various markers which reflect the different pathways of oxidative stress as is oxidosis of lipids, proteins, nucleic acids; yet the antioxidant capacity of various enzymes and vitamins has been studied [9]. However these methods do not reflect oxidative stress as a whole, are time consuming, need special laboratory procedures and are costly.
Oxidation-reduction potential is a new technique that enables bedside assessment of the oxidative status. It is based on measuring the balance of oxidants and reductants in human blood with a simple plasma test that reports results immediately.
Hypothesis
Oxidation-reduction potential, used for oxidative monitoring in ICU patients, might correlate with sepsis severity and may be used in addition to other clinical and/or inflammatory markers to assess severity and possibly prognosis.
Detailed description
- Procedures/evaluation of the trial 4.1 Evaluation at entry
The selected oxidative parameters that will be assessed in this study will be:
oxidation-reduction potential (ORP) in plasma thiobarbituric acid-reactive substances (TBARS) in plasma protein carbonyls (CO) in plasma total antioxidant capacity in plasma (TAC)
The inflammatory parameters that will be measured are:
C-Reactive protein in plasma Brain Natriuretic Peptide (BNP) in whole blood Troponin-I in whole blood Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood
.2. Time of assessment Measurements will be performed within the first 24hours upon entry and daily regarding the ORP detection and oxidative markers for a period of 10 days, if sepsis is not present.
In the presence of sepsis diagnosis, measurements will be performed daily until the 7th day of the septic episode plus at the time of sepsis resolution or at the point of death and at the end of the follow-up period, on the 28th day.
For the inflammatory markers measurements will be performed as followed:
C-Reactive protein in plasma daily Brain Natriuretic Peptide (BNP) in whole blood at admission and/or sepsis diagnosis and every 72h until resolution/death and on the 28th day.
Troponin-I in whole blood at admission and/or sepsis diagnosis and during sepsis according to heart ultrasound findings and on the 28th day.
Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood
4.3. Blood collection and store Arterial blood from an indwelling arterial catheter will be drawn from each patient.
The blood will be kept in a tube with sodium heparin, immediately centrifuged at 1,370g and a small portion will be used for the detection of ORP while the remaining fraction will be collected and stored at -80o C until further analysis.
4.4. Assessment of the oxidative markers ORP will be immediately assessed using the device RedoxSYS of Luoxis (Ampio Pharmaceuticals Inc, CO, USA) The device reports two measurements static ORP, and capacity for every plasma sample [11 ].
For TBARS, a slightly modified assay of Keles et al. [12 ] will be used, while plasma protein carbonyls will be determined based on the method of Patsoukis et al. [13 ]. TAC determination will be based on a previously described method [14].
- Data collection
Data to be recorded for each subject are:
Past medical history Patients wil be divided in medical, surgical and trauma groups. (comprising patients with renal disease, diabetes, Chronic obstructive pulmonary disease, coronary artery disease, immunocompromized states, cerebrovascular disease).
Data to be recorded during ICU stay for each subject, are:
APACHE II score at entry SOFA score at enry and upon all other timepoints. Sepsis severity (sepsis, severe sepsis, septic shock), upon diagnosis and for the rest timepoints.
In all timepoints:
Oxygen concentration (FiO2), partial oxygen pressure , mode of mechanical ventilation, static compliance, tidal volume.
Blood pH Blood lactate Levels of vasopressors and inotropes (noradrenaline, adrenaline, dopamine, dobutamine, vasopressin. The peak dose will be recorded within the last 24h).
Temperature (peak value in the last 24h)
Every day a full blood count and biochemical examinations will take place. Data to be recorded in all timepoints are:
Blood leukocyte count Platelets Fibrinogen Prothrombin time/Partial thromboplastin time Urea/Creatinine Transaminases Bilirubin (total, conjugated) Uric acid Blood albumin (every 3 days).
In addition :
Surveillance cultures upon entry. Blood, bronchial secretions, urine cultures at sepsis diagnosis and of any other fluid or tissue connected with the sepsis cause according to the attending physician. Specimens of all cultures will be repeated during the septic episode according to the attending physician's opinion and will also be recorded.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All subjects who enter to the intensive care unit are candidates for this protocol
Key inclusion criteria (2 listed)
- All subjects entering to the ICU and are expected to stay for more than 72 hours are eligible to participate.
- Sepsis is recognized, defined and categorized according to the Surviving Sepsis Campaign criteria [10].
Key exclusion criteria (1 listed)
- patients who receive chronic renal replacement therapy, iii) age under 18, iv) patients with body mass index<18, v) antioxidant supplementation two weeks prior to ICU admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sepsis severity
Time frame: Time of sepsis diagnosis
2 secondary outcomes
mortality
Time frame: 28th day
ICU outcome
Time frame: within 28 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2014.
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Epaminondas Zakynthinos, Prof. principal investigator
University of Thessaly
Maria Karapetsa, MD principal investigator
University of Thessaly-University Hospital of Larissa,ICU
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis, run by University of Thessaly at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sepsis severity (time frame: Time of sepsis diagnosis). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2014.